Good news for Hong Kong as colorectal cancer treatment approved

With colorectal cancer (MRC) being the second biggest cancer type in Hong Kong, it is positive news that Hutchmed has received marketing approval for its Elunate (fruquintinib) small molecule treatment.

Related Keywords

China ,Hong Kong ,Macau ,United States ,Stephen Chan ,Karen Atkin ,Caron Li ,Drug Administration ,Eli Lilly Company ,China National Medical Products Administration ,Poisons Board ,Honk Kong ,Hong Kong Special Administrative Region ,Eli Lilly ,Clinical Development ,Markets Amp Regulations ,Atient Centricity ,Pis Active Pharmaceutical Ingredients ,Regulations ,Colorectal Cancer ,Hutchmed ,Makeda ,Research ,Dancer ,